Oncoinvent to Participate in Upcoming Virtual Investor Conferences
Oslo, Norway 15, February 2022
• •
upcoming virtual investor conferences:
,
today announced that members of management will participate in two
B. Riley Radiation-Oncology Investor Day. Fireside chat on Tuesday, February 22, 2022 at
10:30 a.m. ET.
2022 Credit Suisse London Healthcare Conference. Company management will participate in
1x1 meetings on Wednesday, March 2, 2022.

4 February 2022
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors

Company adds experienced clinical development expert to its board of directors


Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company’s Extraordinary General Meeting.

Adrian Senderowicz is a US Board certified medical oncologist, and President of Oncology Drug Development, LLC. Adrian is a highly experienced and talented drug development professional with experience in start-ups and late-stage oncology biotech. His 30 years of pharma/biotech/regulatory and clinical trial experience spans discovery/translational research to development and approval of small molecule and antibody-based therapeutics. Previous positions include VP Global Regulatory Oncology at Sanofi and Chief Medical Officer positions in private and public companies such as Ignyta, Cerulean and Tokai. More recently he was the CMO of Constellation pharma, acquired last year by Morphosys Inc. In addition, Adrian was a Medical Officer and Acting Team Leader at the US FDA Division of Oncology Products and an investigator at the US National Cancer Institute. Dr. Senderowicz is currently a board member of Step Pharma and Puma Biotechnology Ltd.

In connection with the new appointment of Dr. Senderowicz, MD Jonas Einarson who has served as non-executive director since 2016, will step down from the board.

Roy H. Larsen, Chairman of Oncoinvent’s Board of Directors, said: “I would like to welcome Adrian to the Board; and I look forward to working with him and the other board members in shaping the future of the company. Dr. Senderowicz is a highly qualified individual who brings experience in key areas that are important for the future development of Oncoinvent, such as clinical development and regulatory affairs. I also, on the behalf of the entire board, want to thank Jonas Einarson for his contribution to the company over a number of years.”



About Oncoinvent

Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versality allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.



For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

Man ser hvor straffa NANOV blir for tiden. En grei påminnelse igjen om at Oncoinvent er eneste selskap som ikke blir påvirket av covid-19, men faktisk ligger foran skjemaet sitt. Ja, du leste riktig! Rekrutteringen går faktisk raskere enn planlagt. Og de er det eneste biotech selskapet som ikke påvirkes av corona pandemien hittil. Hør podcast'en her https://soundcloud.com/user-972208711/episode-183

Drar frem denne tråden og headingen igjen etter at Nanov er forsinket igjen. Oncoinvent er ENESTE biotech selskapet IKKE er forsinket pga covid 19

Google translate:

Pressemelding 9. 2021 Oncoinvent kunngjør fullført registrering i den kliniske fase 1-studien RAD-18-002

Totalt 23 pasienter med kolorektal kreft har blitt registrert i Radspherin® RAD-18-002 fase 1 klinisk studie og behandlet med Radspherin®. Ingen SAE-er relatert til Radspherin®-behandlingen er observert.
Oslo 4, november 2021

Oncoinvent AS, et selskap på klinisk stadium som fremmer en pipeline av radiofarmasøytiske produkter på tvers av en rekke solide kreftformer, kunngjorde i dag at de har fullført rekrutteringen av den kliniske studien Radspherin® RAD-18-002. Alle pasienter som er registrert i studien vil bli fulgt inntil sykdomsprogresjon i bukhulen, eller i 12 måneder etter administrering av Radspherin®, avhengig av hva som kommer først. Biofordelingen og strålingsdosimetrien etter administrering av Radspherin ble undersøkt hos de seks pasientene inkludert i utvidelsesfasen av RAD-18-002-studien. Dosimetridataene vil bli rapportert senere i år.

"Vi er glade for at vi ikke observerte noen SAE-er relatert til Radspherin®, og vi nådde heller ikke en MTD (maksimal tolerert dose) i denne fase 1-studien." uttalte Jan A. Alfheim, administrerende direktør i Oncoinvent. "Dette indikerer at produktet er trygt å bruke i kombinasjon med cytoreduktiv kirurgi og HIPEC (hypertermisk intraperitoneal kjemoterapi) i denne pasientpopulasjonen. Vi er nå i full gang med å forberede oss på neste fase av Radspherin®-utviklingen, der vi vil fokusere på å måle effekten av Radspherin® i behandlingen av peritoneal karsinomatose”.

Om Radspherin®
Radspherin® er en ny alfa-emitterende radioaktiv mikrosfæresuspensjon designet for behandling av metastatisk kreft i kroppshuler. Det radium-224-baserte terapeutiske midlet, Radspherin®, har vist sterk og konsistent antikreftaktivitet ved doser som i hovedsak ikke er toksiske i prekliniske studier. Det er forventet at produktet potensielt kan brukes til å behandle flere former for metastatisk kreft.

Om RAD-18-002-studien
Den åpne fase 1 kliniske studien med doseøkning er utviklet for å vurdere dosen, sikkerheten og toleransen til Radspherin®, en α-emitterende radionuklidterapi, administrert inn i det intraperitoneale hulrommet hos personer med peritoneal karsinomatose fra kolorektal karsinom etter fullstendig cytoreduktiv effekt. kirurgi og HIPEC. Sentrale mål i studien inkluderer å bestemme
maksimal tolerert dose, abdominal biofordeling og foreløpig antitumoraktivitet. Vennligst se www.clinicaltrials.gov for ytterligere detaljer om kliniske studier.

Press Release 9. 2021 Oncoinvent announces completion of enrollment in the RAD-18-002 phase 1 clinical study

Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.
Oslo 4, November 2021

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that it has successfully completed recruitment of the Radspherin® RAD-18-002 clinical study. All patients enrolled in the study will be followed until disease progression in the abdominal cavity, or for 12 months after the administration of Radspherin® whichever comes first. The biodistribution and radiation dosimetry after administration of Radspherin were explored in the six patients included in the expansion phase of the RAD-18-002 study. The dosimetry data will be reported later this year.

“We are pleased that we did not observe any SAE’s related to the Radspherin®, nor did we reach a MTD (maximum tolerated dose) in this phase 1 study.” stated Jan A. Alfheim, Oncoinvent CEO. “This indicates that the product is safe to use in combination with cytoreductive surgery and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) in this patient population. We are now busy preparing for the next phase of Radspherin® development, in which we will turn our focus on measuring the efficacy of Radspherin® in the treatment of peritoneal carcinomatosis”.

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially be used to treat several forms of metastatic cancer.

About the RAD-18-002 Study
The phase 1 open-label, dose-escalation clinical trial is designed to assess the dose, safety, and tolerability of Radspherin®, an α-emitting radionuclide therapy, administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC. Key objectives in the study include determining
maximum tolerated dose, abdominal biodistribution, and preliminary anti-tumor activity. Please refer to www.clinicaltrials.gov for additional clinical trial details.

Google translate:

Pressemelding 7. 2021 Oncoinvent presenterer fire plakater på den 34. årlige kongressen til European Association of Nuclear Medicine

Oncoinvent presenterer prekliniske dosimetridata som dokumenterer en terapeutisk relevant biodistribusjon av Radspherin® samt prekliniske data om de potensielle synergistiske effektene av Radspherin® med eksisterende kreftbehandlinger. Selskapet vil også presentere prekliniske resultater av en ny 212Pb produktkandidat

Oslo 20. oktober 2021

Oncoinvent AS, et selskap på klinisk stadium som fremmer en pipeline av radiofarmasøytiske produkter på tvers av en rekke solide kreftformer, vil presentere nye prekliniske data som støtter den fremtidige kliniske utviklingen av Radspherin®, en ny alfa-emitterende radioaktiv mikrosfæresuspensjon designet for behandling av metastaserende kreftformer i kroppen hulrom, i fire digitale presentasjoner på den 34. årlige kongressen til European Association of Nuclear Medicine (EANM).

"Vi er begeistret over å presentere disse dataene på EANM, og styrke vår tillit til potensialet til alfa-emitterende radioaktive partikler for behandling av metastaserende kreft i kroppshulrom," sa Jan A. Alfheim, administrerende direktør i Oncoinvent. "Disse dataene viser at Radspherin® har potensielt robust og beholdt biodistribusjon i kroppshulrom, og gir oss viktig innsikt i sikkerheten til kliniske doser. Vi ser frem til den fortsatte kliniske utviklingen av Radspherin® hos pasienter med kolorektal og eggstokkreft som lider av peritoneal karsinomatose.»

Synergi av 224Ra-merkede mikropartikler og kjemoterapi i en murin eggstokkreftmodell
Presenterende forfatter: Roxanne Wouters
Abstrakt nummer: OP-0108

Denne prekliniske studien hadde som mål å evaluere effekten av å kombinere 224Ra-CaCO3-MP, radium-224-merkede kalsiumkarbonatmikropartikler, med enten førstelinjekjemoterapi for eggstokkreft, karboplatin-paklitaksel eller andrelinjekjemoterapi, karboplatin-pegylert doxorubicinomal
(PLD), i en eggstokkreftmodell. Ovariekreft musemodeller ble behandlet med 224Ra-CaCO3-MP (5 mg, 14-22 kBq/dyr) en dag etter tumorcelleinokulering. I tillegg ble 224Ra-CaCO3-MP-behandling kombinert med enten karboplatin (100 mg/kg)-paklitaksel (10 mg/kg) på dag 14, 21 eller 28, eller karboplatin (80 mg/kg)-PLD (1,6 mg/kg) ) på dag 14.

Nøkkelresultater:
• Som en enkelt behandling forsinket 224Ra-CaCO3-MP begynnelsen av utviklingen av malign ascites sammenlignet med kontroll.
• Når 224Ra-CaCO3-MP ble administrert i kombinasjon med karboplatin-PLD, ble overlevelsen signifikant forlenget sammenlignet med mus som fikk karboplatin-PLD alene.

Synergi ved behandling av eggstokkreftcellelinjer med Radium-224 og PARP-hemmere
Presenterende forfatter: Marion Masitsa Malenge
Abstrakt nummer: EPS-064

Denne studien evaluerte potensialet ved å kombinere radium-224 (224Ra), en alfa-emitter med 3,6 dagers halveringstid med PARP-hemmere olaparib og niraparib for å hemme vekst av eggstokkreftcellelinjer. Effekten av 224Ra i kombinasjon med olaparib og i kombinasjon med niraparib ble evaluert i to humane ikke-BRCA-muterte eggstokkreftcellelinjer, ES-2 og SKOV-3. Celler ble samtidig behandlet med 224Ra- og PARP-hemmere ved økende konsentrasjoner, og celleproliferasjon ble målt 72, 96 og 120 timer etter behandlingsstart.

Nøkkelresultater:
• Kombinasjonsindeksen (CI) mellom begge evaluerte cellelinjene var heterogen over det testede området avhengig av PARP-hemmeren som ble brukt i kombinasjonen, konsentrasjonene av de kombinerte legemidlene og tidspunktet for vurderingen.
• Kombinasjonsbehandling med PARP-hemmere og 244Ra ble sett å være synergistisk.

Biofordeling og dosimetri etter intraperitoneal injeksjon av 224Ra-merkede mikropartikler i rotter
Presenterende Forfatter: Sara Westrøm
Abstrakt nummer: EP-118

Presentasjonen fremhever ex vivo biodistribusjon 224Ra-CaCO3-MP i prekliniske modeller. I tillegg ble dosimetri beregnet og ekstrapolert til de absorberte dosene til mennesker. 224Ra-CaCO3-MP (89 kBq/dyr, 30 mg CaCO3) eller bærer ble administrert til prekliniske rottemodeller intraperitonealt. Ex vivo biodistribusjon ble vurdert på tidspunkter fra 2 til 336 timer etter
injeksjon. For dosimetriberegninger ble den kumulerte aktiviteten bestemt ved lineær interpolasjon mellom de målte verdiene. Dosimetriresultatene ble ekstrapolert til mennesker og skalering med relativ biologisk effektivitet (RBE) faktorer ble utført.

Nøkkelresultater:
• Størstedelen av 224Ra ble beholdt etter intraperitoneal administrering av 224Ra-CaCO3-MP.
• Analyser av klinisk patologi viste ingen behandlingsrelaterte bivirkninger, bortsett fra en forbigående depresjon av nøytrofiler.
• Dosimetri viste at basert på de lave absorberte dosene for alt vev, anses administrering av opptil 7 MBq 224Ra-CaCO3-MP, maksimal aktivitet i pågående fase 1-studier, som trygg.

Doserespons av 212Pb-merkede kalsiumkarbonatmikropartikler hos mus med intraperitoneal eggstokkreft
Presenterende forfatter: Ruth Gong Li

Press Release 7. 2021 Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine

Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate

Oslo 20, October 2021

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, will present new preclinical data supporting the future clinical development of Radspherin®, a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities, in four digital presentations at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM).

“We are thrilled to present these data at EANM, furthering our confidence in the potential of alpha-emitting radioactive particles for the treatment of metastatic cancers in body cavities,” said Jan A. Alfheim, Chief Executive Officer of Oncoinvent. “These data demonstrate that Radspherin® has potentially robust and retained biodistribution in body cavities, and give us important insights into the safety of clinical doses. We look forward to the continued clinical development of Radspherin® in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.”

Synergy of 224Ra-labeled microparticles and chemotherapy in a murine ovarian cancer model
Presenting Author: Roxanne Wouters
Abstract Number: OP-0108

This preclinical study aimed to evaluate the effects of combining 224Ra-CaCO3-MP, radium-224-labeled calcium carbonate microparticles, with either first line chemotherapy for ovarian cancer, carboplatin-paclitaxel, or second line chemotherapy, carboplatin-pegylated liposomal doxorubicin
(PLD), in an ovarian cancer model. Ovarian cancer mouse models were treated with 224Ra-CaCO3-MP (5 mg, 14-22 kBq/animal) one day following tumor cell inoculation. Additionally, 224Ra-CaCO3-MP treatment was combined with either carboplatin (100 mg/kg)-paclitaxel (10 mg/kg) on day 14, 21 or 28, or carboplatin (80 mg/kg)-PLD (1.6 mg/kg) on day 14.

Key results:
• As a single treatment, 224Ra-CaCO3-MP delayed the onset of malignant ascites development compared to control.
• When 224Ra-CaCO3-MP was administered in combination with carboplatin-PLD, survival was significantly prolonged compared to mice that received carboplatin-PLD alone.

Synergy when treating ovarian cancer cell lines with Radium-224 and PARP inhibitors
Presenting Author: Marion Masitsa Malenge
Abstract Number: EPS-064

This study evaluated the potential of combining radium-224 (224Ra), an alpha-emitter with 3.6 days half-life with the PARP inhibitors olaparib and niraparib to inhibit growth of ovarian cancer cell-lines. The effect of 224Ra in combination with olaparib and in combination with niraparib were evaluated in two human non-BRCA-mutated ovarian cancer cell-lines, ES-2 and SKOV-3. Cells were simultaneously treated with 224Ra and PARP inhibitors at escalating concentrations, and cell proliferation was measured 72, 96 and 120 hours after initiation of treatment.

Key results:
• The combination index (CI) between both evaluated cell-lines was heterogenous across the tested range depending on the PARP inhibitor used in the combination, the concentrations of the combined drugs and the timepoint of assessment.
• Combination treatment with PARP inhibitors and 244Ra was seen to be synergistic.

Biodistribution and dosimetry after intraperitoneal injection of 224Ra-labeled microparticles in rats
Presenting Author: Sara Westrøm
Abstract Number: EP-118

The presentation highlights the ex vivo biodistribution 224Ra-CaCO3-MP in preclinical models. In addition, dosimetry was calculated and extrapolated to the absorbed doses to human. 224Ra-CaCO3-MP (89 kBq/animal, 30 mg CaCO3) or vehicle was administered to preclinical rat models intraperitoneal. Ex vivo biodistribution was assessed at time points ranging from 2 to 336 hours post
injection. For dosimetry calculations, the cumulated activity was determined by linear interpolation between the measured values. The dosimetry results were extrapolated to humans and scaling with relative biologically effectiveness (RBE) factors was performed.

Key results:
• The majority of 224Ra was retained after intraperitoneal administration of 224Ra-CaCO3-MP.
• Analyses of clinical pathology showed no treatment-related adverse effects, apart from a transient depression of neutrophils.
• Dosimetry demonstrated that based on the low absorbed doses for all tissues, administration of up to 7 MBq 224Ra-CaCO3-MP, the maximum activity in ongoing Phase 1 studies, is deemed safe.

Dose response of 212Pb-labeled calcium carbonate microparticles in mice with intraperitoneal ovarian cancer
Presenting Author: Ruth Gong Li
Abstract Number: OP-0111

This study evaluated the intraperitoneal retention and biodistribution of 212Pb-CaCO3 microparticles in mouse models of ovarian cancer. Mice received a single intraperitoneal injection of either 2-5mg with doses ranging from 57-390 kBq 212Pb-CaCO3 microparticles, or vehicle.

Key results:
• Calcium carbonate microparticles can be labeled with 212Pb in an easy, fast and efficient process; no chelator or co-precipitants are necessary.
• 212Pb-CaCO3 microparticles were retained in the peritoneal cavity.
• The increased survival of mice with tumors that were treated with 212Pb-CaCO3 was dose-dependent and significant for all evaluated doses.

Investordagene 2021: «vi bruker radioaktiviet til behandling av kreften, og all teori viser at det fungerer, sier Tore Kvam i Oncoinvent»

Popup mld fra Finansavis app i dag.

Ja, den er ferdig og de fikk inn en liten sum på den.

Ble reperasjonsemisjonen gjennomført ?

4 October 2021
Oncoinvent Strengthens Leadership Team

The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that it has appointed Dr. Kari Myren, MD to the role of Chief Medical Officer, Dr. Anne-Kirsti Aksnes to the role of Vice President Clinical Operations, and Mr. Stian Brekke to the role of Head of Regulatory Affairs.

Dr. Kari Myren is a medical professional with a strong clinical background with specialty training in surgery. She has ten years of experience from leading positions in both the pharmaceutical and MedTech industries relating to oncology and early phase immuno-oncology, as well as clinical experience from oncologic surgery. Dr. Myren has previously held the positions of Medical Advisor and Senior Medical Advisor at Novartis and Roche Diagnostics respectively. Dr. Myren comes to Oncoinvent from Photocure ASA where she held the position of Vice President Global Medical Affairs and Clinical Development.

Dr. Anne-Kirsti Aksnes is a multi-disciplinary clinical research professional with more than 20 years of experience within clinical research and development in the pharmaceutical and biotech industry. Dr. Aksnes has a strong knowledge of all aspects of clinical development and operations and a broad and reputable experiences with clinical studies in all phases (I-IV). She is a physiologist by training with a Medical Doctorate Degree (PhD) from Karolinska Institute in Sweden. Dr. Aksnes has held multiple senior positions including VP Clinical Development at Targovax ASA and Director of Clinical Research at G.E. Healthcare. Dr. Aksnes also held the position of VP Clinical Development at Algeta ASA and was responsible for the clinical development of Xofigo, a product that has gone on to become the world’s most successful and largest selling radiopharmaceutical.

Mr. Stian Brekke has worked in regulatory affairs since 2005, as a regulatory affairs manager, regulatory project leader and QPPV during 11 years in Pharmaq AS, and since April 2019 as a regulatory affairs director at SMERUD, based in Oslo, Norway. Mr. Brekke has led multiple regulatory submissions to various competent authorities, including marketing authorisation applications, orphan drug designation applications, variation applications, clinical trial applications etc. He has ensured regulatory compliance in close collaboration with clinical R&D units, specialized laboratories, consultants, and regulatory authorities as the regulatory representative in drug development projects.

“I am very pleased that we have been able to attract qualified and experienced people such as Kari, Anne-Kirsti, and Stian to our team,” said Jan A. Alfheim, Chief Executive Officer of Oncoinvent. “I am looking forward to working with them to build Oncoinvent into a world leader in alpha-emitting radiotherapeutics. I would like to use this opportunity to thank Dr. Øyvind Bruland for all his efforts in the development of Radspherin® to date, and I look forward to continuing our fine collaboration as he steps into his new role as Senior Medical Advisor and Head of the Radspherin® Clinical Advisory Board for Oncoinvent”

Alfheim continued by saying, “I would also like to thank Kari Skinnemoen, our former Head of Regulatory Affairs for all her excellent work and contributions to the development of Radspherin@ these past four years and I look forward to her continued contributions to the Radspherin® development as she begins her transition to retirement.”

På norsk fra google translate:

Oncoinvent kunngjør avansering av Radspherin® til fjerde dosekohorte i pågående RAD-18-001 fase 1-prøve hos pasienter med kreft i eggstokkene

Sikkerhetsovervåkningskomiteens gjennomgang av tredje kohorte på dosnivå tillater progresjon av fase 1 RAD-18-001-studie til fjerde og siste kohortdosenivåkohort

Oslo 27, september 2021

Oncoinvent AS, et selskap i klinisk fase som utvikler en rørledning av radiofarmaka, på tvers av en rekke faste kreftformer, kunngjorde i dag at prøveovervåkingskomiteen for rettssaken godkjente sin første fase 1-i-kliniske studie av Radspherin® hos kreft i eggstokkene som lider av peritoneal karsinomatose. for å gå videre til fjerde nivå dosekohorte. Registrering i denne kohorten, hvor pasientene vil motta 7 MBq Radspherin®, forventes å begynne umiddelbart.

"Utviklingen av RAD-18-001-studien til det fjerde doseringsnivået, fortsetter å bygge vår selvtillit når vi fortsetter å utvikle Radspherin® for behandling av peritoneal karsinomatose, et område med stort uoppfylt behov," sier Jan A. Alfheim, administrerende direktør. Offiser i Oncoinvent. "Vi vil nå begynne å dosere pasienter på dosenivået på 7 MBq, et dosenivå som har vist seg å være trygt for pasienter med tykktarmskreft."

Om RAD-18-001

Fase 1, åpen, dose-eskalering klinisk studie er designet for å vurdere dosen, sikkerheten og toleransen for Radspherin®, en α-emitterende radionuklidbehandling, administrert i intraperitonealhulen hos personer med peritoneal karsinomatose fra eggstokkreft etter fullstendig cytoreduktiv kirurgi . Hovedmål i studien inkluderer å bestemme maksimal tolerert dose, biodistribusjon i magen og foreløpig antitumoraktivitet. Se www.clinicaltrials.gov for ytterligere detaljer om kliniske studier.

https://podcasts.apple.com/no/podcast/radium/id1483387944?l=nb&i=1000535289642

Radforsk episode 190 ute i dag! Oncoinvent fra ca 2,5 minutter. «rekruttering går over all forventning» «safety vært bra, ingen skjær i sjøen» «ting fungerer som forventet på forhånd»

Send mail til kvam@oncoinvent.com om man vil ha teamslink til presentasjonen kl 0900 i dag.

https://podcasts.apple.com/no/podcast/radium/id1483387944?l=nb&i=1000534699113

Ny episode av radforsk. Oncoinvent fra rundt 28 minutter. Q2-tall i morgen også.

Snart ei uke siden fristen. Noen som hørt noe ang resultatet?

Husk sist frist i morgen! https://www.oncoinvent.com/investors/transaction/

Tegningskurs 52,-. Sist omsatt 55,- nå.

Få dager igjen av rep. emisjonen for de som vil delta:

From 09:00 hours (CEST) on 23. August 2021 to 16:30 hours (CEST) on 3. September 2021

For de som vil kjøpe, kan kontakte Simen.Skagestad@arctic.com, +47 47399375. Pareto har også bra opplegg med handel på aksjen. Og det kan man følge med på kjøp- og selgerbildet i aksjen.